Prof Greg Monteith

B. Pharm PhD



About me

Greg’s research team at UQ seeks to identify and characterise novel therapeutic targets for the treatment of cancer. A particular focus of his research group is the identification of new drug targets for breast cancer subtypes for which there are few effective therapies and the prognosis is poor.

Greg uses a variety of approaches to identify calcium channels and pumps that may be targets for cancer drug development. His research team consists of PhD students and post-doctoral researchers from a diverse array of backgrounds including Pharmacy, Biotechnology, Biochemistry, Chemistry, Microbiology and Pharmacology. Members of his group are studying specific calcium pumps and channels as new drug targets, calcium signaling pathways in cancer cells and new approaches in biomolecular high throughput screening. 

PhD students and post-doctoral researchers who join his research group will be trained in methods to image calcium signaling in living cells, molecular pharmacology techniques and pharmaceutical industry relevant bioassays for drug discovery.

Training in his laboratory is well suited for students and early career researchers considering careers in biomedical research and/or pharmaceutical industry drug discovery programs.The group’s work is published in leading scientific journals including Nature Reviews Cancer, Journal of Biology Chemistry and Trends in Pharmacological Sciences.

His laboratory has received over $ 7 million dollars in research funding, and is currently supported by the National Health and Medical Research Council of Australia, Australian Research Council and the Cancer Council of Queensland.


Selected Publications

Davis FM, Janoshazi A, Janardhan KS, Steinckwich N, D'Agostin DM, Petranka JG, Desai PN, Roberts-Thomson SJ, Bird GS, Tucker DK, Fenton SE, Feske S, Monteith GR, Putney JW Jr. Essential role of Orai1 store-operated calcium channels in lactation. Proc Natl Acad Sci USA. 2015 112(18):5827-32

Davis FM, Stewart TA, Thompson EW, Monteith GR. Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci. 35:479-88, 2014.

Azimi I, Roberts-Thomson SJ, Monteith GR. Calcium influx pathways in breast cancer: opportunities for pharmacological intervention. Br J Pharmacol. 171:945-60.,2014

Davis FM, Azimi I, Faville RA, Peters AA, Jalink K, Putney JW Jr, Goodhill GJ, Thompson EW, Roberts-Thomson SJ, Monteith GR. Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent. Oncogene. 2014 33(18):2307-16.

Peters AA, Simpson PT, Bassett JJ, Lee JM, Da Silva L, Reid LE, Song S, Parat MO, Lakhani SR, Kenny PA, Roberts-Thomson SJ, Monteith GR. Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. Mol Cancer Ther.;11:2158-68, 2012

Feng M, Grice D, Faddy H, Nguyen N, Leitch S, Wang Y, Muend S, Kenny P, Sukumar S, Roberts-Thomson SJ, Monteith GR, Rao R. Store-Independent Activation of Orai1 by SPCA2 in Mammary Tumors. Cell. 143: 84-98. 2010  

Monteith GR, McAndrew D, Faddy HM, Roberts-Thomson SJ. Calcium and cancer: targeting Ca2+ transport. Nature Reviews Cancer. 7:519-30, 2007  

Monteith GR and Bird St J. High throughput measurement of calcium: back to basics. Trends in Pharmacological Sciences 26(4):218-23, 2005


Research fields

molecular pharmacology, breast cancer, calcium signalling, signal transduction, drug discovery